Search
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedAripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. … Affecting about 1% of the adult population in the United States and approximately 26 million people worldwide, schizophrenia is a chronic neurological disorder that may result in impairments in cognition
Prazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigationalPrazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. … Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624]
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. … Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in
Products: Miochol E, MIOCHOL EPanitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalThis drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]
Cyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Anthoxanthum odoratum
go.drugbank.com/drugs/DB14163ApprovedAnthoxanthum odoratum allergenic extract is used in allergenic testing.
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalAlthough multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment
Conivaptan
go.drugbank.com/drugs/DB00872ApprovedIt was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).
Products: Vaprisol Dextrose In Plastic ContainerAxatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigationalAxatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.
Hemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.